Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment

Oncolytic viruses (OVs) are novel anti-tumor agents with the ability to selectively infect and kill tumor cells while sparing normal tissue. Beyond tumor cytolysis, OVs are capable of priming an anti-tumor immune response via lysis and cross-presentation of locally expressed endogenous tumor antigen...

Descripción completa

Detalles Bibliográficos
Autores principales: De Lucia, Maria, Cotugno, Gabriella, Bignone, Veronica, Garzia, Irene, Nocchi, Linda, Langone, Francesca, Petrovic, Biljana, Sasso, Emanuele, Pepe, Simona, Froechlich, Guendalina, Gentile, Chiara, Zambrano, Nicola, Campadelli-Fiume, Gabriella, Nicosia, Alfredo, Scarselli, Elisa, D’Alise, Anna Morena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658578/
https://www.ncbi.nlm.nih.gov/pubmed/33209980
http://dx.doi.org/10.1016/j.omto.2020.10.006
_version_ 1783608702841913344
author De Lucia, Maria
Cotugno, Gabriella
Bignone, Veronica
Garzia, Irene
Nocchi, Linda
Langone, Francesca
Petrovic, Biljana
Sasso, Emanuele
Pepe, Simona
Froechlich, Guendalina
Gentile, Chiara
Zambrano, Nicola
Campadelli-Fiume, Gabriella
Nicosia, Alfredo
Scarselli, Elisa
D’Alise, Anna Morena
author_facet De Lucia, Maria
Cotugno, Gabriella
Bignone, Veronica
Garzia, Irene
Nocchi, Linda
Langone, Francesca
Petrovic, Biljana
Sasso, Emanuele
Pepe, Simona
Froechlich, Guendalina
Gentile, Chiara
Zambrano, Nicola
Campadelli-Fiume, Gabriella
Nicosia, Alfredo
Scarselli, Elisa
D’Alise, Anna Morena
author_sort De Lucia, Maria
collection PubMed
description Oncolytic viruses (OVs) are novel anti-tumor agents with the ability to selectively infect and kill tumor cells while sparing normal tissue. Beyond tumor cytolysis, OVs are capable of priming an anti-tumor immune response via lysis and cross-presentation of locally expressed endogenous tumor antigens, acting as an “endovaccine.” The effectiveness of OVs, similar to other immunotherapies, can be hampered by an immunosuppressive tumor microenvironment. In this study, we modified a previously generated oncolytic herpes simplex virus (oHSV) retargeted to the human HER2 (hHER2) tumor molecule and encoding murine interleukin-12 (mIL-12), by insertion of a second immunomodulatory molecule, murine granulocyte-macrophage colony-stimulating factor (mGM-CSF), to maximize therapeutic efficacy. We assessed the efficacy of this double-armed virus (R-123) compared to singly expressing GM-CSF and IL-12 oHSVs in tumor-bearing mice. While monotherapies were poorly effective, combination with α-PD1 enhanced the anti-tumor response, with the highest efficacy of 100% response rate achieved by the combination of R-123 and α-PD1. Efficacy was T cell-dependent, and the induced immunity was long lasting and able to reject a second contralateral tumor. Importantly, systemic delivery of R-123 combined with α-PD1 was effective in inhibiting the development of tumor metastasis. As such, this approach could have a significant therapeutic impact paving the way for further development of this platform in cancer immunotherapy.
format Online
Article
Text
id pubmed-7658578
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society of Gene & Cell Therapy
record_format MEDLINE/PubMed
spelling pubmed-76585782020-11-17 Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment De Lucia, Maria Cotugno, Gabriella Bignone, Veronica Garzia, Irene Nocchi, Linda Langone, Francesca Petrovic, Biljana Sasso, Emanuele Pepe, Simona Froechlich, Guendalina Gentile, Chiara Zambrano, Nicola Campadelli-Fiume, Gabriella Nicosia, Alfredo Scarselli, Elisa D’Alise, Anna Morena Mol Ther Oncolytics Original Article Oncolytic viruses (OVs) are novel anti-tumor agents with the ability to selectively infect and kill tumor cells while sparing normal tissue. Beyond tumor cytolysis, OVs are capable of priming an anti-tumor immune response via lysis and cross-presentation of locally expressed endogenous tumor antigens, acting as an “endovaccine.” The effectiveness of OVs, similar to other immunotherapies, can be hampered by an immunosuppressive tumor microenvironment. In this study, we modified a previously generated oncolytic herpes simplex virus (oHSV) retargeted to the human HER2 (hHER2) tumor molecule and encoding murine interleukin-12 (mIL-12), by insertion of a second immunomodulatory molecule, murine granulocyte-macrophage colony-stimulating factor (mGM-CSF), to maximize therapeutic efficacy. We assessed the efficacy of this double-armed virus (R-123) compared to singly expressing GM-CSF and IL-12 oHSVs in tumor-bearing mice. While monotherapies were poorly effective, combination with α-PD1 enhanced the anti-tumor response, with the highest efficacy of 100% response rate achieved by the combination of R-123 and α-PD1. Efficacy was T cell-dependent, and the induced immunity was long lasting and able to reject a second contralateral tumor. Importantly, systemic delivery of R-123 combined with α-PD1 was effective in inhibiting the development of tumor metastasis. As such, this approach could have a significant therapeutic impact paving the way for further development of this platform in cancer immunotherapy. American Society of Gene & Cell Therapy 2020-10-14 /pmc/articles/PMC7658578/ /pubmed/33209980 http://dx.doi.org/10.1016/j.omto.2020.10.006 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
De Lucia, Maria
Cotugno, Gabriella
Bignone, Veronica
Garzia, Irene
Nocchi, Linda
Langone, Francesca
Petrovic, Biljana
Sasso, Emanuele
Pepe, Simona
Froechlich, Guendalina
Gentile, Chiara
Zambrano, Nicola
Campadelli-Fiume, Gabriella
Nicosia, Alfredo
Scarselli, Elisa
D’Alise, Anna Morena
Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment
title Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment
title_full Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment
title_fullStr Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment
title_full_unstemmed Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment
title_short Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment
title_sort retargeted and multi-cytokine-armed herpes virus is a potent cancer endovaccine for local and systemic anti-tumor treatment
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658578/
https://www.ncbi.nlm.nih.gov/pubmed/33209980
http://dx.doi.org/10.1016/j.omto.2020.10.006
work_keys_str_mv AT deluciamaria retargetedandmulticytokinearmedherpesvirusisapotentcancerendovaccineforlocalandsystemicantitumortreatment
AT cotugnogabriella retargetedandmulticytokinearmedherpesvirusisapotentcancerendovaccineforlocalandsystemicantitumortreatment
AT bignoneveronica retargetedandmulticytokinearmedherpesvirusisapotentcancerendovaccineforlocalandsystemicantitumortreatment
AT garziairene retargetedandmulticytokinearmedherpesvirusisapotentcancerendovaccineforlocalandsystemicantitumortreatment
AT nocchilinda retargetedandmulticytokinearmedherpesvirusisapotentcancerendovaccineforlocalandsystemicantitumortreatment
AT langonefrancesca retargetedandmulticytokinearmedherpesvirusisapotentcancerendovaccineforlocalandsystemicantitumortreatment
AT petrovicbiljana retargetedandmulticytokinearmedherpesvirusisapotentcancerendovaccineforlocalandsystemicantitumortreatment
AT sassoemanuele retargetedandmulticytokinearmedherpesvirusisapotentcancerendovaccineforlocalandsystemicantitumortreatment
AT pepesimona retargetedandmulticytokinearmedherpesvirusisapotentcancerendovaccineforlocalandsystemicantitumortreatment
AT froechlichguendalina retargetedandmulticytokinearmedherpesvirusisapotentcancerendovaccineforlocalandsystemicantitumortreatment
AT gentilechiara retargetedandmulticytokinearmedherpesvirusisapotentcancerendovaccineforlocalandsystemicantitumortreatment
AT zambranonicola retargetedandmulticytokinearmedherpesvirusisapotentcancerendovaccineforlocalandsystemicantitumortreatment
AT campadellifiumegabriella retargetedandmulticytokinearmedherpesvirusisapotentcancerendovaccineforlocalandsystemicantitumortreatment
AT nicosiaalfredo retargetedandmulticytokinearmedherpesvirusisapotentcancerendovaccineforlocalandsystemicantitumortreatment
AT scarsellielisa retargetedandmulticytokinearmedherpesvirusisapotentcancerendovaccineforlocalandsystemicantitumortreatment
AT daliseannamorena retargetedandmulticytokinearmedherpesvirusisapotentcancerendovaccineforlocalandsystemicantitumortreatment